Coronary Thrombolysis with Tissue-Type Plasminogen Activator: Prospective Review
AUTOR(ES)
Collen, Désiré
RESUMO
Coronary thrombolysis is not a goal in itself, but is employed to prevent necrotic dysfunction of jeopardized myocardial cells. It is being increasingly investigated as a treatment for acute myocardial infarction, which is often associated with thrombotic occlusion of an atherosclerotic coronary artery. The administration of thrombolytic agents has been shown to reopen an occluded coronary artery in the majority of such cases. Briefly summarized are studies performed to date in animal models and in patients with acute myocardial infarction.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=351707Documentos Relacionados
- Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.
- Tissue-type plasminogen activator: a role for O-linked fucose.
- Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
- Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
- Origins of the specificity of tissue-type plasminogen activator.